A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
Hui Jing Yu(Vaxine (Australia)), Jean‐Cosme Dodart(Merritt College)
Cited by 51
Related Papers
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
|DOAJ (DOAJ: Directory of Open Access Journals)|2022|76
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
|Alzheimer s Research & Therapy|2020|48
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
|Frontiers in Neuroscience|2021|40